Alexander & Baldwin, Inc. (NYSE: ALEX) ("A&B" or "Company"), a Hawai'i-based owner, operator, and developer of high-quality commercial real estate in Hawai'i, today announced that its management...

SAMBAZON®, the pioneer of Açaí, made waves in Southern California this past weekend with its first-ever Experiential Pop-Up Activation, a high-energy, three-day celebration held May 16th –...

Veeva Systems (NYSE: VEEV) today announced participation in the following investor conferences: Baird 2025 Global Consumer, Technology & Services Conference, New York, NY. Paul Shawah, EVP...

Creatv Bio, a Division of Creatv MicroTech, Inc. ("Creatv") in collaboration with CytoDyn Inc. ("CytoDyn") presents promising four-year survival rates from a pooled clinical trial analysis of...

The Special Competitive Studies Project (SCSP), a non-partisan, non-profit project dedicated to strengthening America's long-term competitiveness in artificial intelligence (AI), announced new and...

The RV owners group reveals plans for upcoming events in Wyoming, Georgia, and Missouri. CINCINNATI, May 30, 2025 /PRNewswire/ -- Family RV Association (FRVA) is gearing up for its 111th...

Outside Festival -- Backroads, the global leader in active travel for all ages, today announced the launch of a new trip collection for adults in their 30s and 40s. Handpicked from the company's...

Adela, Inc., an innovator in blood testing for molecular residual disease (MRD) monitoring and early cancer detection through a proprietary genome-wide methylome enrichment technology, is...

IMGS-001 is first dual-specific PD-L1/PD-L2 antibody with cytotoxic killing function and is designed to treat the many "immune-excluded" cancers that are resistant to existing immunotherapies HOUSTON,

New test offerings target solid tumors and hematologic malignancies Enhanced biopharma services support accelerated clinical trials and companion diagnostic development BURLINGTON, N.C., May 30,...